108 related articles for article (PubMed ID: 7534433)
1. [Hydroxyurea, erythrocyte volumes and hemoglobin F].
Bargetzi MJ; Schönenberger A; Tichelli A; Passweg J; Rabaglio M; Singer D; Sissolak G; Gratwohl A; Speck B
Schweiz Med Wochenschr; 1995 Mar; 125(9):433-5. PubMed ID: 7534433
[TBL] [Abstract][Full Text] [Related]
2. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.
Steinberg MH; Voskaridou E; Kutlar A; Loukopoulos D; Koshy M; Ballas SK; Castro O; Barton F
Am J Hematol; 2003 Feb; 72(2):121-6. PubMed ID: 12555216
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
Charache S
Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
[TBL] [Abstract][Full Text] [Related]
4. Clinical response and adverse events in young patients with sickle cell disease treated with hydroxyurea.
Kattamis A; Lagona E; Orfanou I; Psichou F; Ladis V; Kanavakis E; Metaxotou-Mavrommati A; Kattamis C
Pediatr Hematol Oncol; 2004 Jun; 21(4):335-42. PubMed ID: 15205096
[TBL] [Abstract][Full Text] [Related]
5. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia.
Ballas SK; McCarthy WF; Guo N; Brugnara C; Kling G; Bauserman RL; Waclawiw MA
Hemoglobin; 2010; 34(5):424-9. PubMed ID: 20854115
[TBL] [Abstract][Full Text] [Related]
6. [beta-thalassemia minor diagnosed in a patient with chronic myelogenous leukemia during hydroxyurea therapy].
Chiba K; Kurosawa M; Kondo T; Suzuki S; Musashi M; Asaka M; Imamura M; Hattori Y; Oba Y
Rinsho Ketsueki; 2000 Jan; 41(1):61-4. PubMed ID: 10695401
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
Rogers ZR
Semin Hematol; 1997 Jul; 34(3 Suppl 3):42-7. PubMed ID: 9317200
[TBL] [Abstract][Full Text] [Related]
8. The activity of superoxide dismutase in hydroxyurea-treated E beta thalassemia.
Ajanta H; Chakraborty S; Madhusnata D; Bhattacharya DK; Manisha D
J Assoc Physicians India; 2002 Aug; 50():1034-5. PubMed ID: 12421025
[TBL] [Abstract][Full Text] [Related]
9. Lack of influence of fetal hemoglobin levels or erythrocyte indices on the severity of sickle cell anemia.
Powars DR; Schroeder WA; Weiss JN; Chan LS; Azen SP
J Clin Invest; 1980 Mar; 65(3):732-40. PubMed ID: 6153392
[TBL] [Abstract][Full Text] [Related]
10. In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients.
Watanapokasin Y; Chuncharunee S; Sanmund D; Kongnium W; Winichagoon P; Rodgers GP; Fucharoen S
Exp Hematol; 2005 Dec; 33(12):1486-92. PubMed ID: 16338491
[TBL] [Abstract][Full Text] [Related]
11. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
[TBL] [Abstract][Full Text] [Related]
13. The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease.
Vasavda N; Badiger S; Rees D; Height S; Howard J; Thein SL
Br J Haematol; 2008 Nov; 143(4):589-92. PubMed ID: 18764867
[TBL] [Abstract][Full Text] [Related]
14. Induction of fetal hemoglobin synthesis with recombinant human erythropoietin in anemic patients with heterozygous beta-thalassemia during pregnancy.
Breymann C; Fibach E; Visca E; Huettner C; Huch A; Huch R
J Matern Fetal Med; 1999; 8(1):1-7. PubMed ID: 10052837
[TBL] [Abstract][Full Text] [Related]
15. Can Couples With MCV≥80, MCH<26, HbA2<3.2, HbF<3 be Classified as Low-risk β-Thalassemia Group?
Mirzakhani M; Tarrahi MJ; Baghersad A; Maracy MR
J Pediatr Hematol Oncol; 2019 May; 41(4):303-306. PubMed ID: 30676434
[TBL] [Abstract][Full Text] [Related]
16. Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide.
Voskaridou E; Terpos E; Komninaka V; Eftyhiadis E; Mantzourani M; Loukopoulos D
Br J Haematol; 2002 Jan; 116(1):155-7. PubMed ID: 11841409
[TBL] [Abstract][Full Text] [Related]
17. Measuring hydroxyurea adherence by pharmacy and laboratory data compared with video observation in children with sickle cell disease.
Creary S; Chisolm D; Stanek J; Neville K; Garg U; Hankins JS; O'Brien SH
Pediatr Blood Cancer; 2020 Aug; 67(8):e28250. PubMed ID: 32386106
[TBL] [Abstract][Full Text] [Related]
18. Flow cytometric analysis of fetal hemoglobin in erythroid precursors of beta-thalassemia.
Amoyal I; Fibach E
Clin Lab Haematol; 2004 Jun; 26(3):187-93. PubMed ID: 15163316
[TBL] [Abstract][Full Text] [Related]
19. Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease.
Triadou P; Maier-Redelsperger M; Krishnamoorty R; Deschamps A; Casadevall N; Dunda O; Ducrocq R; Elion J; Girot R; Labie D
Nouv Rev Fr Hematol (1978); 1994 Oct; 36(5):367-72. PubMed ID: 7534399
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea responses and fetal hemoglobin induction in beta-thalassemia/HbE patients' peripheral blood erythroid cell culture.
Watanapokasin R; Sanmund D; Winichagoon P; Muta K; Fucharoen S
Ann Hematol; 2006 Mar; 85(3):164-9. PubMed ID: 16389564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
